PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — BridgeBio Pharma Inc. (BBIO) on Tuesday reported a loss of $181.9 million in its second quarter.
The Palo Alto, California-based company said it had a loss of 95 cents per share.
The results fell short of Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 83 cents per share.
The rare disease drug developer posted revenue of $110.6 million in the period, beating Street forecasts. Eight analysts surveyed by Zacks expected $96.2 million.
BridgeBio Pharma shares have risen 79% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $49.21, a rise of 93% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BBIO at https://www.zacks.com/ap/BBIO
/Intel%20Corp_%20Santa%20Clara%20campus-by%20jejim%20via%20Shutterstock.jpg)
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/The%20CrowdStrike%20logo%20on%20an%20office%20building%20by%20bluestork%20via%20Shutterstock.jpg)